R Squared’s Quest Diagnostics DGX Stock Holding History

R Squared’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,713	Closed	-$471K	–	538
2025 Q4	$471K	Buy	+2,713	New	+$494K	0.22%	128

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

R Squared's DGX Position: Q1 2026 in Review

R Squared sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 2,713 shares — an estimated $471K sold.

R Squared first reported a position in DGX in Q4 2025 and held it in 1 quarter. The position peaked at $471K in Q4 2025. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

R Squared reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
R Squared sold 2,713 Quest Diagnostics shares in Q1 2026, an estimated $471K.
R Squared first reported a position in Quest Diagnostics in Q4 2025 and held it in 1 quarter.
R Squared's Quest Diagnostics position peaked at $471K in Q4 2025.
1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.